Autoimmune Hemolytic Anemias

Blood Banking and Transfusion Medicine

Volumn , Issue , 2007, Pages 557-570

  Silberstein, Leslie E ^a,b   Cunningham, Melody J ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882524355     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06981-9.50046-6     Document Type: Chapter

References (174)

1. Sloan S, Silberstein LE Transfusion: in the face of autoantibodies. Red Cell Transfusion: A Practical Guide 1998, Humana Press, Totowa, N.J. M. Reid, S.J. Nance (Eds.).
2. Coombs R, Mourant AE, Race RR A new test for the detection of weak and incomplete Rh agglutinins. Br J Exp Pathol 1945, 26:255.
3. Boorman K, Dodd BE, Loutit JF Hemolytic icterus (acholuric jaundice): congenital and acquired. Lancet 1946, 1:812.
4. Lewis R, Henry WB, Thornton GW, et al. A syndrome of autoimmune hemolytic anemia and thrombocytopenia in dogs. Proc J Am Vet Med Assoc 1963, 1:140.
5. Bielschowsky M, Helyer BJ, Howie JB Spontaneous hemolytic anemia in mice of the NZB/Bl strain. Proc Univ Otago Med Sch 1959, 37:9.
6. Petschner F, Walter UA, Schmitt-Graff A, et al. "Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab. Dtsch Med Wochenschr 2001, 126:998-1001.
7. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98:952-957.
8. Sackey K Hemolytic anemia: part 1. Pediatr Rev 1999, 20:152-159.
9. Pirofsky B Auto immunization and the Autoimmune Hemolytic Anemias 1969, Williams & Wilkins, Baltimore.
10. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995, 91:341-344.
11. Robak T, Blasinska-Morawiec M, Krykowski E, et al. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 1997, 58:109-113.
12. Drobyski WR, Potluri J, Sauer D, et al. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 17:1093-1099.
13. Sokol RJ, Stamps R, Booker DJ, et al. Posttransplant immune-mediated hemolysis. Transfusion 2002, 42:198-204.
14. Beckers EA, van Guvdener C, Overbeeke MA, et al. Intravascular hemo-lysis by IgA red cell autoantibodies. Neth J Med 2001, 58:204-207.
15. In Immunobiology: the Immune System in Health and Disease 1999, Garland Publishing, New York. 4th ed. C. Janeway, P. Travers, M. Walport, J.D. Capra (Eds.).
16. Domen RE An overview of immune hemolytic anemias. Cleve Clin J Med 1998, 65:89-99.
17. Huber H, Polley MJ, Linscott WD, et al. Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science 1968, 162:1281-1283.
18. LoBuglio AF, Cotran RS, Jandl JH Red cells coated with immunoglob-ulin G: binding and sphering by mononuclear cells in man. Science 1967, 158:1582-1585.
19. Fleer A, van der Meulen FW, Linthout E, et al. Destruction of IgG-sensitized erythrocytes by human blood monocytes: modulation of inhibition by IgG. Br J Haematol 1978, 39:425-436.
20. Schreiber AD, Frank MM Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest 1972, 51:575-582.
21. Schreiber AD, Frank MM Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest 1972, 51:583-589.
22. Meite M, Leonard S, Idrissi ME, et al. Exacerbation of autoanti-body- mediated hemolytic anemia by viral infection. J Virol 2000, 74:6045-6049.
23. Brown DL, Lachmann PJ, Dacie JV The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol 1970, 7:401-421.
24. Munn LR, Chaplin H Rosette formation by sensitized human red cells-effects of source of peripheral leukocyte monolayers. Vo x Sang 1977, 33:129-142.
25. Gorst DW, Rawlinson VI, Merry AH, et al. Positive direct antiglobulin test in normal individuals. Vox Sang 1980, 38:99-105.
26. Unger LJ A method for detecting Rho antibodies in extremely low titer. J Lab Clin Med 1951, 37:825-837.
27. Issitt PD, et al. Anti-Wrb and other autoantibodies responsible for positive direct antiglobulin tests in 150 individuals. Br J Haematol 1976, 34:5-18.
28. Smith MA, Shah NS, Lobel JS Parvovirus B19 infection associated with reticulocytopenia and chronic autoimmune hemolytic anemia. Am J Pediatr Hematol Oncol 1989, 11:167-169.
29. Roush GR, Rosenthal NS, Gerson SL, et al. An unusual case of autoimmune hemolytic anemia with reticulocytopenia, erythroid dysplasia, and an IgG2 autoanti-U. Transfusion 1996, 36:575-580.
30. Conley CL, Lippman SM, Ness P Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA 1980, 244:1688-1690.
31. Conley CL, Lippman SM, Ness PM, et al. Autoimmune hemolytic anemia with reticulocytopenia and erythroid marrow. NEJM 1982, 306:281-286.
32. Crosby WH, Rappaport H Reticulocytopenia in autoimmune hemo-lytic anemia. Blood 1956, 11:929-936.
33. Mangan KF, Besa EC, Shadduck RK, et al. Demonstration of two distinct antibodies in autoimmune hemolytic anemia with reticulocyto-penia and red cell aplasia. Exp Hematol 1984, 12:788-793.
34. Van De Loosdrecht AA, Hendriks DW, Blom NR, et al. Excessive apopto-sis of bone marrow erythroblasts in a patient with autoimmune haemo-lytic anaemia with reticulocytopenia. Br J Haematol 2000, 108:313-315.
35. Frank M NIH conference. Pathophysiology of immune hemolytic anemia. Ann Intern Med 1977, 87:210-222.
36. Pruzanski W, Shumak KH Biologic activity of cold-reacting autoanti-bodies (first of two parts). NEJM 1977, 297:538-542.
37. Crisp D, Pruzanski W B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 1982, 72:915-922.
38. Silberstein LE, Goldman J, Kant JA, et al. Comparative biochemical and genetic characterization of clonally related human B-cell lines secreting patho genic anti-Pr2 cold agglutinins. Arch Biochem Bio-phys 1988, 264:244-252.
39. Silberstein LE, Robertson GA, Harris AC, et al. Etiologic aspects of cold agglutinin disease: evidence for cytogenetically defined clones of lymphoid cells and the demonstration that an anti-Pr cold autoanti-body is derived from a chromosomally aberrant B cell clone. Blood 1986, 67:1705-1709.
40. Rosenthal MC, Pisciotta AV, Komninos ZD, et al. The auto-immune hemolytic anemia of malignant lymphocytic disease. Blood 1955, 10:197-227.
41. Hamblin TJ, Oscier DG, Young BJ Autoimmunity in chronic lympho-cytic leukaemia. J Clin Pathol 1986, 39:713-716.
42. Sikora K, Krikorian J, Levy R Monoclonal immunoglobulin rescue from a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia. Blood 1979, 54:513-518.
43. Petz LD Transfusing the patient with autoimmune hemolytic anemia. Clin Lab Med 1982, 2:193-210.
44. Plapp FV, Beck ML Transfusion support in the management of immune haemolytic disorders. Clin Haematol 1984, 13:167-183.
45. Rosenfield RE, Jagathambal Transfusion therapy for autoimmune hemolytic anemia. Semin Hematol 1976, 13:311-321.
46. Sokol RJ, Hewitt S, Booker DJ, et al. Patients with red cell autoantibodies: selection of blood for transfusion. Clin Lab Haematol 1988, 10:257-264.
47. Dacie JV, Cutbush M Specificity of auto-antibodies in acquired hae-molytic anaemia. J Clin Pathol 1954, 7:18-21.
48. Hogman C, Killander J, Sjolin S A case of idiopathic auto-immune haemolytic anaemia due to anti-e. Acta Paediatr 1960, 49:270-280.
49. Sachs V Anti-C as a sole autoantibody in autoimmune hemolytic anemia. Transfusion 1985, 25:587-588.
50. Weiner W, Battey DA, Cleghorn TE, et al. Serological findings in a case of haemolytic anaemia, with some general observations on the patho-genesis of this syndrome. BMJ 1953, 2:125-128.
51. Issitt P, Anstee DJ Applied Blood Group Serol-ogy 1998, Scientific Publications, Durham, N.C. 4th ed. Montgomery (Ed.).
52. James P, Rowe GP, Tozzo GG Elucidation of alloantibodies in autoimmune haemolytic anaemia. Vox Sang 1988, 54:167-171.
53. Laine ML, Beattie KM Frequency of alloantibodies accompanying autoantibodies. Transfusion 1985, 25:545-546.
54. Wallhermfechtel MA, Pohl BA, Chaplin H Alloimmunization in patients with warm autoantibodies. A retrospective study employing three donor alloabsorptions to aid in antibody detection. Transfusion 1984, 24:482-485.
55. Mollison PL Measurement of survival and destruction of red cells in haemolytic syndromes. Br Med Bull 1959, 15:59-67.
56. Acquired Immune Hemolytic Anemias 1980, Churchill Livingstone, New York. L. Petz, G. Garratty (Eds.).
57. Gould SA, Rosen AL, Sehgal LR, et al. Fluosol-DA as a red-cell substitute in acute anemia. NEJM 1986, 314:1653-1656.
58. Mullon J, Giacoppe G, Clagett C, et al. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. NEJM 2000, 342:1638-1643.
59. Klein HG The prospects for red-cell substitutes. NEJM 2000, 342:1666-1668.
60. Atkinson JP, Schreiber AD, Frank MM Effects of corticosteroids and splenectomy on the immune clearance and destruction of erythro-cytes. J Clin Invest 1973, 52:1509-1517.
61. Fries LF, Brickman CM, Frank MM Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy. J Immunol 1983, 131:1240-1245.
62. Schreiber AD Clinical immunology of the corticosteroids. Prog Clin Immunol 1977, 3:103-114.
63. Schreiber AD, Parsons J, McDermott P, et al. Effect of corticosteroids on the human monocyte IgG and complement receptors. J Clin Invest 1975, 56:1189-1197.
64. Collins PW, Newland AC Treatment modalities of autoimmune blood disorders. Semin Hematol 1992, 29:64-74.
65. Schwartz SI, Bernard RP, Adams JT, et al. Splenectomy for hematologic disorders. Arch Surg 1970, 101:247-338.
66. American Academy of Pediatrics: Red Book: report of the Committee on Infectious Diseases 1997, Committee on Infectious Disease, American Academy of Pediatrics, Elk Grove Village, Ill. 24th ed.
67. Parker A, MacPherson AI, Richmond J Value of radiochromium investigation in autoimmune haemolytic anemia. BMJ 1977, 6055:208.
68. Gopal AK, Press OW Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999, 134:445-450.
69. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999, 26:66-73.
70. Dillman RO Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999, 18:465-471.
71. Dillman RO Monoclonal antibodies in the treatment of malignancy: Basic concepts and recent developments. Cancer Invest 2001, 19:833-841.
72. Waldmann T, Levy R, Coller BS Emerging therapies: spectrum of applications of monoclonal antibody therapy. In Hematology (Am Soc Hematol Educ Program) 2000, 394.
73. Hagberg H, Holmbom E Risk factors for side effects during first infusion of rituximab-definition of a low risk group. Med Oncol 2000, 17:218-221.
74. Berentsen S, Tjonnfjord GE, Brudevold R, et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001, 115:79-83.
75. Borradori L, Lombardi T, Samson J, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001, 137:269-272.
76. Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001, 66:142-144.
77. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001, 358:1511-1513.
78. Zecca M, De Stefano P, Nobili B, Locatelli F Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001, 97:3995-3997.
79. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003, 101:3857-3861.
80. Besa EC Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am J Med 1988, 84:691-698.
81. Samuelsson A, Towers TL, Ravetch JV Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
82. Murphy S, LoBuglio AF Drug therapy of autoimmune hemolytic anemia. Semin Hematol 1976, 13:323-334.
83. Fauci AS, Dale DC, Wolff SM Cyclophosphamide and lymphocyte subpopulations in Wegener's granulomatosis. Arthritis Rheum 1974, 17:355-361.
84. Steinberg A Cytotoxic drugs in treatment of nonmalignant diseases. Ann Intern Med 1972, 76:619-642.
85. Fahey JL Cancer in the immunosuppressed patient. Ann Intern Med 1971, 75:310-312.
86. Floersheim GL A comparative study of the effects of anti-tumour and immunosuppressive drugs on antibody-forming and erythropoietic cells. Clin Exp Immunol 1970, 6:861-870.
87. Miller JJ, Williams GF, Leissring JC Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am J Med 1971, 50:530-535.
88. Qureshi M, Pennington JH, Goldsmith HJ, Cox PE Cyclophophamide. Lancet 1972, 7790:1290.
89. Johnson WW, Meadows DC Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy. NEJM 1971, 284:290-294.
90. Emilia G, et al. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 1996, 93:341-344.
91. Orlin JB, Berkman EM Partial plasma exchange using albumin replacement: removal and recovery of normal plasma constituents. Blood 1980, 56:1055-1059.
92. Silberstein LE, Berkman EM Plasma exchange in autoimmune hemolytic anemia (AIHA). J Clin Apher 1983, 1:238-242.
93. Kutti J, Wadenvik H, Safai-Kutti S, et al. Successful treatment of refractory autoimmune haemolytic anaemia by plasmapheresis. Scand J Haematol 1984, 32:149-152.
94. Rapoport AP, Rowe JM, McMican A Life-threatening autoimmune hemolytic anemia in a patient with the acquired immune deficiency syndrome. Transfusion 1988, 28:190-191.
95. Capra JD, Dowling P, Cook S, et al. An incomplete cold-reactive gamma G antibody with i specificity in infectious mononucleosis. Vox Sang 1969, 16:10-17.
96. Rosenfield RE, Schmidt PJ, Calvo RC, et al. Anti-i, a frequent cold agglutinin in infectious mononucleosis. Vox Sang 1965, 10:631-634.
97. Silberstein LE, Shoenfeld Y, Schwartz RS, et al. A combination of IgG and IgM autoantibodies in chronic cold agglutinin disease: Immunologic studies and response to splenectomy. Vox Sang 1985, 48:105-109.
98. Szymanski IO, Teno R, Rybak ME Hemolytic anemia due to a mixture of low-titer IgG lambda and IgM lambda agglutinins reacting optimally at 22°C. Vox Sang 1986, 51:112-116.
99. Tschirhart DL, Kunkel L, Shulman IA Immune hemolytic anemia associated with biclonal cold autoagglutinins. Vox Sang 1990, 59:222-226.
100. Deutsch HF Properties and modifications of a cryomacroglobulin possessing cold agglutinin activity. Biopolymers 1969, 7:21-37.
101. Kuenn JW, Weber R, Teague PO, et al. Cryopathic gangrene with an IgM lambda cryoprecipitating cold agglutinin. Cancer 1978, 42:1826-1833.
102. Tsai CM, Zopf DA, Yu RK, et al. A Waldenström macroglobulin that is both a cold agglutinin and a cryoglobulin because it binds N-acetyl-neuraminosyl residues. Proc Natl Acad Sci USA 1977, 74:4591-4594.
103. Umlas J, Kaufman M, MacQueston C, et al. A cryoglobulin with cold agglutinin and erythroid stem cell suppressant properties. Transfusion 1991, 31:361-364.
104. Ruddy S, Gigli I, Austen KF The complement system of man. I. NEJM 1972, 287:489-495.
105. Borsos T, Rapp HJ Complement fixation on cell surfaces by 19S and 7S antibodies. Science 1965, 150:505-506.
106. Konig AL, Kather H, Roelcke D Autoimmune hemolytic anemia by coexisting anti-I and anti-Fl cold agglutinins. Blut 1984, 49:363-368.
107. Sokol RJ, Booker DJ, Stamps R The pathology of autoimmune haemolytic anaemia. J Clin Pathol 1992, 45:1047-1052.
108. Abramson N, Gelfand EW, Jandl JH, et al. The interaction between human monocytes and red cells. Specificity for IgG subclasses and IgG fragments. J Exp Med 1970, 132:1207-1215.
109. Atkinson JP, Frank MM Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest 1974, 54:339-348.
110. Ambrus M, Bajtain G A case of an IgG-type cold agglutinin disease. Haematologia 1969, 3:225.
111. Angevine CD, Andersen BR, Barnett EV A cold agglutinin of the IgA class. J Immunol 1966, 96:578-586.
112. Dellagi K, Brouet JC, Schenmetzler C, et al. Chronic hemolytic anemia due to a monoclonal IgG cold agglutinin with anti-Pr specificity. Blood 1981, 57:189-191.
113. Garratty G, Petz LD, Brodsky I, et al. An IgA high-titer cold agglutinin with an unusual blood group specificity within the Pr complex. Vox Sang 1973, 25:32-38.
114. Moore J, Chaplin H Autoimmune hemolytic anemia associated with an IgG cold incomplete antibody. Vox Sang 1973, 24:236.
115. Pruzanski W, Cowan DH, Parr DM Clinical and immunochemical studies of IgM cold agglutinins with λ type light chains. Clin Immunol Immunopathol 1974, 2:234-245.
116. Shulman IA, et al. Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA 1985, 253:1746-1748.
117. Silberstein LE, Berkman EM, Schreiber AD Cold hemagglutinin disease associated with IgG cold-reactive antibody. Ann Intern Med 1987, 106:238-242.
118. Tonthat H, et al. A new case of monoclonal IgAK cold agglutinin with anti-Pr1d specificity in a patient with persistent HB antigen cirrhosis. Vox Sang 1976, 30:464-468.
119. Andrzejewski C, Gault E, Briggs M, et al. Benefit of a 37°C extracorporeal circuit in plasma exchange therapy for selected cases with cold agglutinin disease. J Clin Apher 1988, 4:13-17.
120. Park JV, Weiss CI Cardiopulmonary bypass and myocardial protection: management problems in cardiac surgical patients with cold autoimmune disease. Anesth Analg 1988, 67:75-78.
121. Hippe E, Jensen KB, Olesen H, et al. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood 1970, 35:68-72.
122. Schubothe H The cold hemagglutinin disease. Semin Hematol 1966, 3:27-47.
123. Berentsen S, Ulvestad E, Gjersten BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004, 103:2925-2928.
124. Godder K, Pati AR, Abhyankar SH, et al. De novo chronic graft-ver-sus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant. Bone Marrow Transplant 1997, 19:813-817.
125. Gottsche B, Salama A, Mueller-Eckhardt C Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases. Vox Sang 1990, 58:281-286.
126. Heddle NM Acute paroxysmal cold hemoglobinuria. Transfus Med Rev 1989, 3:219-229.
127. Nordhagen R, Stensvold K, Winsnes A, et al. Paroxysmal cold haemo-globinuria. The most frequent acute autoimmune haemolytic anaemia in children?. Acta Paediatr Scand 1984, 73:258-262.
128. Hinz D, Picken MD, Lepow IH Studies on immune human hemolysis II: the Donath-Landsteiner reaction as a model system for studying the mechanism of action of complement and the role of C1 and C1 esterase. J Exp Med 1961, 113:193.
129. Levine P, Celano MJ, Falkowski F The specificity of the antibody in paroxysmal cold hemoglobinuria (PCH). Transfusion 1963, 3:278-280.
130. Worlledge SM, Rousso C Studies on the serology of paroxysmal cold haemoglobinuria (PGH), with special reference to its relationship with the P blood group system. Vox Sang 1965, 10:293-298.
131. Engelfriet CP, Borne AV, Moes M, et al. Serological studies in autoimmune haemolytic anaemia. Bibl Haematol 1968, 29:473-478.
132. Judd WJ, Wilkinson SL, Issitt PD, et al. Donath-Landsteiner hemo-lytic anemia due to an anti-Pr-like biphasic hemolysin. Transfusion 1986, 26:423-425.
133. Weiner W, Gordon EG, Rowe D A Donath-Landsteiner antibody (non-syphilitic type). Vox Sang 1964, 9:684-697.
134. Petz LD, Fudenberg HH Coombs-positive hemolytic anemia caused by penicillin administration. NEJM 1966, 274:171-178.
135. Bougie D, Johnson ST, Weitekamp LA, et al. Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 1997, 90:407-413.
136. Salama A, Mueller-Eckhardt C On the mechanisms of sensitization and attachment of antibodies to RBC in drug-induced immune hemo-lytic anemia. Blood 1987, 69:1006-1010.
137. Carstairs K, Breckenridge A, Dollery CT, Worlledge SM Incidence of a positive direct Coombs test in patients on alpha-methyldopa. Lancet 1966, 7455:133.
138. Petz LD Drug-induced immune haemolytic anaemia. Clin Haematol 1980, 9:455-482.
139. Worlledge SM Immune drug-induced hemolytic anemias. Semin Hematol 1973, 10:327-344.
140. Danielson DA, Douglas SW, Herzog P, et al. Drug-induced blood disorders. JAMA 1984, 252:3257-3260.
141. Theofilopoulos AN, Dixon FJ Murine models of systemic lupus ery-thematosus. Adv Immunol 1985, 37:269-390.
142. Okamoto M, Murakami M, Shimizu A, et al. A transgenic model of autoimmune hemolytic anemia. J Exp Med 1992, 175:71-79.
143. Sakiyama T, Ikuta K, Nisitani S, et al. Requirement of IL-5 for induction of autoimmune hemolytic anemia in anti-red blood cell autoanti-body transgenic mice. Int Immunol 1999, 11:995-1000.
144. Nisitani S, Honjo T Breakage of B cell tolerance and autoantibody production in anti-erythrocyte transgenic mice. Int Rev Immunol 1999, 18:259-270.
145. Nisitani S, Sakiyama T, Honjo T Involvement of IL-10 in induction of autoimmune hemolytic anemia in anti-erythrocyte Ig transgenic mice. Int Immunol 1998, 10:1039-1047.
146. Leddy JP, Falany JL, Kissel GE, et al. Erythrocyte membrane proteins reactive with human (warm-reacting) anti-red cell autoantibodies. J Clin Invest 1993, 91:1672-1680.
147. Bloy C, Blanchard D, Lambin P, et al. Human monoclonal antibody against Rh(D) antigen: partial characterization of the Rh(D) polypep-tide from human erythrocytes. Blood 1987, 69:1491-1497.
148. Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. NEJM 1983, 309:453-458.
149. Kipps TJ, Carson DA Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993, 81:2475-2487.
150. Leddy JP, Bakemeier RF Structural aspects of human erythrocyte autoantibodies. I. L chain types and electrophoretic dispersion. J Exp Med 1965, 121:1-17.
151. Masouredis SP, Branks MJ, Victoria EJ Antiidiotypic IgG crossreactive with Rh alloantibodies in red cell autoimmunity. Blood 1987, 70:710-715.
152. Hakomori S Blood group ABH and Ii antigens of human erythrocytes: Chemistry, polymorphism, and their developmental change. Semin Hematol 1981, 18:39-62.
153. Stevenson FK, Smith GJ, North J, et al. Identification of normal B-cell counterparts of neoplastic cells which secrete cold agglutinins of anti-I and anti-i specificity. Br J Haematol 1989, 72:9-15.
154. Costea N, Yakulis VJ, Heller P Inhibition of cold agglutinins (anti-I) by M. pneumoniae antigens. Proc Soc Exp Biol Med 1972, 139:476-479.
155. 4-21gene segment is responsible for the major cross-reactive idiotype. J Immunol 1991, 146:4385-4391.
156. Silberstein LE, Jefferies LC, Goldman J, et al. Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood 1991, 78:2372-2386.
157. Stevenson FK, Spellerberg MB, Treasure J, et al. Differential usage of an Ig heavy chain variable region gene by human B-cell tumors. Blood 1993, 82:224-230.
158. Perrotta S, Locatelli F, La Manna A, et al. Anti-CD20 monoclonal anti body (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002, 116:465-467.
159. Motto DG, Williams JA, Boxer LA Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J 2002, 4:1006-1008.
160. McMahon C, Babu L, Hodgson A, et al. Childhood refractory autoimmune haemolytic anaemia: is there a role for anti-CD20 therapy (rituximab)?. Br J Haematol 2002, 117:480-483.
161. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocyto-penia. Haematologica 2002, 87:189-195.
162. Corti P, Bonanomi S, Vallinoto C, et al. Rituximab for immune hemo-lytic anemia following T- and B-cell-depleted hematopoietic stem cell transplantation. Acta Haematol 2003, 109:43-45.
163. Hongeng S, Tardtong P, Worapongpaiboon S, et al. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant 2002, 29:871-872.
164. Ship A, May W, Lucas K Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. Bone Marrow Transplant 2002, 29:365-366.
165. Lee EJ, Kueck B Rituxan in the treatment of cold agglutinin disease. Blood 1998, 92:3490-3491.
166. Layios N, Van Den NE, Jost E, et al. Remission of severe cold agglutinin disease after rituximab therapy. Leukemia 2001, 15:187-188.
167. Zaja F, Russo D, Fuga G, et al. Rituximab in a case of cold agglutinin disease. Br J Haematol 2001, 115:232-233.
168. Bauduer F Rituximab: A very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. Br J Haematol 2001, 112:1085-1086.
169. Chemnitz J, Draube A, Diehl V, Wolf J Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol 2002, 69:232-233.
170. Pulik M, Genet P, Lionnet F, Touahri T Treatment of primary chronic cold agglutinin disease with rituximab: maintenance therapy may improve the results. Br J Haematol 2002, 117:998-999.
171. Engelhardt M, Jakob A, Ruter B, et al. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood 2002, 100:1922-1923.
172. Gharib M, Poynton C Complete, long-term remission of refractory idiopathic cold haemagglutinin disease after Mabthera. Br J Haematol 2002, 117:248-249.
173. Berentsen S, Tjonnfjord GE, Brudevold R, et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001, 115:79-83.
174. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lympho-cytic leukemia. Leukemia 2002, 16:2092-2095.